MicroRNA-21 drives severe, steroid-insensitive experimental asthma by amplifying phosphoinositide 3-kinase–mediated suppression of histone deacetylase 2
File(s)Kim miR-21 paper JACI accepted version.pdf (7.9 MB)
Accepted version
Author(s)
Type
Journal Article
Abstract
BACKGROUND: Severe steroid-insensitive asthma is a substantial clinical problem. Effective treatments are urgently required, however, their development is hampered by a lack of understanding of the mechanisms of disease pathogenesis. Steroid-insensitive asthma is associated with respiratory tract infections and noneosinophilic endotypes, including neutrophilic forms of disease. However, steroid-insensitive patients with eosinophil-enriched inflammation have also been described. The mechanisms that underpin infection-induced, severe steroid-insensitive asthma can be elucidated by using mouse models of disease. OBJECTIVE: We sought to develop representative mouse models of severe, steroid-insensitive asthma and to use them to identify pathogenic mechanisms and investigate new treatment approaches. METHODS: Novel mouse models of Chlamydia, Haemophilus influenzae, influenza, and respiratory syncytial virus respiratory tract infections and ovalbumin-induced, severe, steroid-insensitive allergic airway disease (SSIAAD) in BALB/c mice were developed and interrogated. RESULTS: Infection induced increases in the levels of microRNA (miRNA)-21 (miR-21) expression in the lung during SSIAAD, whereas expression of the miR-21 target phosphatase and tensin homolog was reduced. This was associated with an increase in levels of phosphorylated Akt, an indicator of phosphoinositide 3-kinase (PI3K) activity, and decreased nuclear histone deacetylase (HDAC)2 levels. Treatment with an miR-21-specific antagomir (Ant-21) increased phosphatase and tensin homolog levels. Treatment with Ant-21, or the pan-PI3K inhibitor LY294002, reduced PI3K activity and restored HDAC2 levels. This led to suppression of airway hyperresponsiveness and restored steroid sensitivity to allergic airway disease. These observations were replicated with SSIAAD associated with 4 different pathogens. CONCLUSION: We identify a previously unrecognized role for an miR-21/PI3K/HDAC2 axis in SSIAAD. Our data highlight miR-21 as a novel therapeutic target for the treatment of this form of asthma.
Date Issued
2016-06-10
Date Acceptance
2016-04-29
Citation
Journal of Allergy and Clinical Immunology, 2016, 139 (2), pp.519-532
ISSN
1097-6825
Publisher
Elsevier
Start Page
519
End Page
532
Journal / Book Title
Journal of Allergy and Clinical Immunology
Volume
139
Issue
2
Copyright Statement
© 2016 Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/
Sponsor
Medical Research Council (MRC)
Commission of the European Communities
Medical Research Council (MRC)
Grant Number
G1000758
115010
G1000758
Subjects
Science & Technology
Life Sciences & Biomedicine
Allergy
Immunology
Severe asthma
corticosteroids
airway hyperresponsiveness
miR-21
PI3 kinase
histone deacetylase 2
Chlamydia
species
Haemophilus influenzae
influenza
respiratory syncytial virus
OBSTRUCTIVE PULMONARY-DISEASE
ALLERGIC AIRWAYS DISEASE
REGULATORY T-CELLS
INFLUENZA-VIRUS INFECTION
RESPIRATORY-INFECTION
INFLAMMATORY RESPONSES
BACTERIAL-INFECTION
NEUTROPHILIC ASTHMA
IMMUNE-RESPONSE
TENSIN HOMOLOG
Chlamydia species
Animals
Antagomirs
Asthma
Chlamydia muridarum
Dexamethasone
Disease Models, Animal
Drug Resistance
Gene Expression Regulation
Histone Deacetylase 2
Humans
Influenza A Virus, H1N1 Subtype
Mice
Mice, Inbred BALB C
MicroRNAs
PTEN Phosphohydrolase
Phosphatidylinositol 3-Kinases
Phosphorylation
Pneumonia
Proto-Oncogene Proteins c-akt
Respiratory Syncytial Viruses
Respiratory Tract Infections
1107 Immunology
Publication Status
Published